Opus Genetics (IRD) News Today $1.95 -0.06 (-2.99%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$1.96 +0.01 (+0.51%) As of 10/22/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $7.75October 21 at 2:22 AM | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Research Coverage Started at Chardan CapitalOctober 19, 2025 | americanbankingnews.comOpus Genetics initiated with a Buy at ChardanOctober 16, 2025 | msn.comChardan Capital Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationOctober 16, 2025 | msn.comOpus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 16, 2025 | marketbeat.comChardan Capital Begins Coverage on Opus Genetics (NASDAQ:IRD)October 16, 2025 | marketbeat.comOpus Genetics to Participate in Chardan's 9th Annual Genetic Medicines ConferenceOctober 14, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Given Sell (D-) Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comOpus Genetics, Inc. (NASDAQ:IRD) Sees Large Increase in Short InterestOctober 6, 2025 | marketbeat.comOpus Genetics (NASDAQ:IRD) Trading Up 4.4% - Should You Buy?October 4, 2025 | marketbeat.comOpus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025October 2, 2025 | globenewswire.comOpus Genetics, Inc. - Special CallSeptember 30, 2025 | seekingalpha.comOpus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)September 30, 2025 | globenewswire.comInstitutions profited after Opus Genetics, Inc.'s (NASDAQ:IRD) market cap rose US$15m last week but private equity firms profited the mostSeptember 26, 2025 | finance.yahoo.comInstitutions profited after Opus Genetics, Inc.'s (NASDAQ:IRD) market cap rose US$15m last week but private equity firms profited the mostSeptember 26, 2025 | finance.yahoo.comOpus Genetics reports inducement grant under Nasdaq listing rulesSeptember 12, 2025 | msn.comOpus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 12, 2025 | globenewswire.comAWM Investment Company Inc. Acquires Shares of 524,245 Opus Genetics, Inc. $IRDSeptember 5, 2025 | marketbeat.comOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under ...September 4, 2025 | finance.yahoo.comOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsSeptember 4, 2025 | globenewswire.comOpus Genetics Appoints New Chief Financial OfficerSeptember 3, 2025 | msn.comOpus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comNantahala Capital Management LLC Purchases Shares of 3,157,895 Opus Genetics, Inc. $IRDSeptember 3, 2025 | marketbeat.comOpus Genetics Appoints Rob Gagnon as Chief Financial OfficerSeptember 2, 2025 | globenewswire.comBIOS Capital Management LP Invests $977,000 in Opus Genetics, Inc. $IRDAugust 28, 2025 | marketbeat.comOpus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in SeptemberAugust 27, 2025 | globenewswire.comMink Brook Asset Management LLC Acquires Shares of 810,080 Opus Genetics, Inc. $IRDAugust 26, 2025 | marketbeat.comOpus Genetics, Inc.: Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1August 18, 2025 | finanznachrichten.deOpus Genetics announces FDA clearance of IND application for OPGx-BEST1August 18, 2025 | msn.comOpus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1August 18, 2025 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 16, 2025 | finance.yahoo.comOpus Genetics (NASDAQ:IRD) Issues Earnings ResultsAugust 15, 2025 | marketbeat.comOpus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deOpus Genetics reports Q2 EPS (12c) vs (30c) last yearAugust 14, 2025 | msn.comOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14, 2025 | finance.yahoo.comOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comOpus Genetics (IRD) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comOpus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 5, 2025 | globenewswire.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 24, 2025 | finance.yahoo.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Raised to "Hold" at Wall Street ZenJuly 12, 2025 | marketbeat.comOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comOpus Genetics, Inc. (IRD) Income Statement - Yahoo FinanceJune 30, 2025 | finance.yahoo.comOpus Genetics (NASDAQ:IRD) Stock Rating Lowered by Wall Street ZenJune 28, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)June 27, 2025 | marketbeat.comOpus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJune 26, 2025 | globenewswire.comOpus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK ProgramJune 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Trading 1% Higher - What's Next?June 6, 2025 | marketbeat.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...June 4, 2025 | seekingalpha.com Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Media Mentions By Week IRD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRD News Sentiment▼0.330.52▲Average Medical News Sentiment IRD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRD Articles This Week▼72▲IRD Articles Average Week Get the Latest News and Ratings for IRD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Opus Genetics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ocugen News Inventiva News ADC Therapeutics News CryoPort News Fulcrum Therapeutics News MBX Biosciences News Lexeo Therapeutics News 4D Molecular Therapeutics News Rocket Pharmaceuticals News Cullinan Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRD) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts